NASDAQ:KLRS Kalaris Therapeutics Q3 2025 Earnings Results & Report $1.58 -0.09 (-5.12%) Closing price 11/13/2026 04:00 PM EasternExtended Trading$1.58 0.00 (0.00%) As of 11/13/2026 04:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Kalaris Therapeutics beat analyst earnings expectations in its Q3 2025 results, released November 12, 2025. The company reported EPS of -$0.64 versus the -$0.66 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2025Report DateNovember 12, 2025TimeBefore Market Opens Kalaris Therapeutics EPS ResultsActual EPS-$0.64Consensus EPS -$0.66Beat/MissBeat by +$0.02One Year Ago EPSN/AEPS Beat Rate5 of last 6 quartersKalaris Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile Kalaris Therapeutics Q3 2025 Earnings FAQ Did Kalaris Therapeutics beat earnings estimates for Q3 2025? Kalaris Therapeutics (NASDAQ:KLRS) reported earnings of -$0.64 per share for Q3 2025, beating the consensus estimate of -$0.66. The report was announced on Wednesday, November 12, 2025. Kalaris Therapeutics Earnings HeadlinesKalaris Therapeutics IncNovember 12 at 9:36 AM | markets.ft.comKalaris Therapeutics Reports Q3 Net LossNovember 10, 2026 | rttnews.comExecutive Order 14241 Unleashes Trump’s New DollarA landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December. The agenda at the upcoming G20 Summit in Miami has shifted, and new research points to a major monetary announcement from President Trump. A new documentary breaks down what this shift could mean for savings, investments, and the assets tied to it.November 14 at 1:00 AM | Porter & Company (Ad)Kalaris Reports Third Quarter 2026 Financial Results and Provides Business UpdateNovember 10, 2026 | globenewswire.comKalaris Therapeutics (NASDAQ:KLRS) Stock Rating Lowered by Wall Street ZenNovember 8, 2026 | americanbankingnews.comKalaris Therapeutics Inc (KLRS)October 3, 2026 | investing.comSee More Kalaris Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Kalaris Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kalaris Therapeutics and other key companies, straight to your email. Email Address About Kalaris TherapeuticsKalaris Therapeutics (NASDAQ:KLRS) is a clinical-stage biopharmaceutical company focused on developing treatments for retinal diseases. Its work centers on advancing investigational therapies intended to address conditions affecting vision. The company’s product candidates are in development and are not approved for commercial use. Kalaris’s activities include research and development and the clinical evaluation of potential therapies. Publicly available information about the company’s leadership and geographic operations is limited.View Kalaris Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/13Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCerebras Q3 Results: How Much More Proof Does Wall Street Need?YETI Beat on Earnings, But Its Sales Tell a Different StoryCostco's Record $30 Dividend Shows Just How Strong Its Cash Machine IsLightPath Technologies' Record Backlog Highlights a Bigger Defense Opportunity Upcoming Earnings Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
